Health insurance and Medicaid; require coverage for postpartum depression screenings.
Summary
House Bill 1578 would require Mississippi insurers and the Medicaid program to treat postpartum depression screening and treatment more directly in coverage and utilization rules. The bill prohibits step therapy, or “fail-first,” requirements for any FDA-approved drug used to treat postpartum depression. It also requires physicians, health care providers, and nurse midwives who provide postnatal care or pediatric infant care to offer postpartum depression screening to the mother or postnatal patient, and to conduct screening consistent with evidence-based guidelines if the patient does not object. If screening suggests postpartum depression, the provider must make appropriate referrals and discuss available treatments, including medication.
The bill also requires insurers to cover postpartum depression screening and provide additional reimbursement for administering the screening. In the Medicaid statute, it adds postpartum depression screening coverage as a covered service and directs the Division of Medicaid and managed care entities to reimburse providers for screening. It further amends Mississippi’s general step-therapy law so that postpartum depression medications are exempt from step-therapy restrictions, while leaving the existing override process in place for other drugs and conditions. The act is set to take effect July 1, 2025.
Impact
HB1578 would amend Sections 43-13-117 and 83-9-36 of the Mississippi Code to add postpartum depression screening and treatment protections into both Medicaid and private insurance law. For Medicaid, the bill adds postpartum depression screening as a covered service, requires reimbursement for screening administration, and bars step therapy for FDA-approved postpartum depression drugs in Medicaid and managed care. For private coverage, it requires insurers to cover postpartum depression screening and creates an explicit exemption from step-therapy restrictions for postpartum depression medications. The bill would affect insurers, managed care entities, Medicaid providers, postnatal patients, birthing mothers, and pediatric infant care providers.
Sentiment
The bill’s stated purpose and structure indicate generally supportive sentiment toward expanding maternal mental health screening and treatment access. The caption and text frame the measure as a coverage and access bill focused on postpartum depression, and the absence of recorded committee debate or votes suggests no documented opposition in the provided materials. The bill appears designed to reduce barriers to care and encourage earlier identification and treatment of postpartum depression.
Contention
The main policy tension in the bill is between access to postpartum depression treatment and insurer utilization controls. By prohibiting step therapy for postpartum depression drugs, the bill limits insurers’ ability to require patients to try lower-cost or preferred medications first, which could raise concerns from insurers and managed care organizations about cost management and formulary control. A second possible point of contention is the mandate that providers offer screening and that insurers reimburse for it, which could raise administrative and cost concerns for providers and payers. No specific objections, amendments, or recorded vote opposition are included in the provided history.